Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EyePoint Pharmaceuticals, Inc. (EYPT)
USD13.52
-0.21 (-1.50%)
US NASDAQ Healthcare Biotechnology
Address
480 Pleasant Street 2472
Watertown, MA, US
Watertown, MA, US
CEO
Jay S. Duker
Website
eyepointpharma.com
IPO
2005-01-27
CIK 1314102 ISIN US30233G2093
Description
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD13.52
-0.21 (-1.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.75
Float Shares
73.60M
Free Float %
87.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.34% | +4.41% | -1.48% | +7.46% | +16.60% | -23.48% | +138.97% | +138.16% | +58.50% | -49.89% | -96.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
13.52
Low
36.00
+166.2%
Consensus
37.50
+177.3%
Median
37.50
+177.3%
High
39.00
+188.4%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
36.00
+166.2%
|
| Last Year | 4 |
34.00
+151.4%
|
| All Time | 8 |
30.38
+124.6%
|
Quality scores
Altman Z-Score
4.11
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-27.5% Q1'26: -97.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-36.6% Q1'26: -52.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-884.5% Q1'26: -11,716.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-776.0% Q1'26: -12,532.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1,170.4% Q1'26: -1,239.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+30.1% Q1'26: +23.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 8 EPS Ana. |
Dec 2027 7 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.57M
est: 26.80M (-0.9%)
|
1.62M
est: 2.78M (-41.8%)
|
7.54M
est: 7.33M (+2.9%)
|
2.96M
est: 2.96M (+0.0%)
|
20.37M
est: 18.85M (+8.0%)
|
34.44M
est: 45.60M (-24.5%)
|
36.94M
est: 35.19M (+5.0%)
|
41.40M
est: 41.28M (+0.3%)
|
46.02M
est: 50.39M (-8.7%)
|
43.27M
est: 42.55M (+1.7%)
|
31.37M
est: 31.77M (-1.2%)
|
1.55M
1.18M – 1.91M
-95.1% YoY
|
47.67M
1.12M – 115.44M
+2,983.5% YoY
|
284.82M
12.33M – 758.74M
+497.5% YoY
|
564.35M
24.42M – 1.50B
+98.1% YoY
|
845.67M
36.60M – 2.25B
+49.8% YoY
|
| EBITDA |
-20.87M
est: -26.80M (+22.1%)
|
-17.67M
est: -2.78M (-534.9%)
|
-18.58M
est: -7.33M (-153.6%)
|
-36.99M
est: -2.96M (-1,149.4%)
|
-48.01M
est: -18.85M (-154.7%)
|
-35.49M
est: -45.60M (+22.2%)
|
-50.15M
est: -35.19M (-42.5%)
|
-96.62M
est: -56.26M (-71.7%)
|
-69.00M
est: -50.39M (-36.9%)
|
-129.23M
est: -42.55M (-203.7%)
|
-243.43M
est: -31.77M (-666.3%)
|
-1.55M
-1.91M – -1.18M
+95.1% YoY
|
-47.67M
-115.44M – -1.12M
-2,983.5% YoY
|
-284.82M
-758.74M – -12.33M
-497.5% YoY
|
-564.35M
-1.50B – -24.42M
-98.1% YoY
|
-845.67M
-2.25B – -36.60M
-49.8% YoY
|
| EBIT |
-21.70M
est: -26.80M (+19.0%)
|
-18.49M
est: -2.78M (-564.2%)
|
-52.45M
est: -7.33M (-616.0%)
|
-39.02M
est: -2.96M (-1,217.8%)
|
-50.62M
est: -18.85M (-168.5%)
|
-38.14M
est: -45.60M (+16.4%)
|
-52.92M
est: -35.19M (-50.4%)
|
-99.07M
est: -57.19M (-73.2%)
|
-69.47M
est: -50.39M (-37.9%)
|
-130.77M
est: -42.55M (-207.4%)
|
-243.43M
est: -31.77M (-666.3%)
|
-1.55M
-1.91M – -1.18M
+95.1% YoY
|
-47.67M
-115.44M – -1.12M
-2,983.5% YoY
|
-284.82M
-758.74M – -12.33M
-497.5% YoY
|
-564.35M
-1.50B – -24.42M
-98.1% YoY
|
-845.67M
-2.25B – -36.60M
-49.8% YoY
|
| Net Income |
6.35M
est: -22.52M (+128.2%)
|
-21.55M
est: -346.23M (+93.8%)
|
-18.49M
est: -289.00M (+93.6%)
|
-53.17M
est: -647.43M (+91.8%)
|
-56.79M
est: -319.49M (+82.2%)
|
-45.39M
est: -102.46M (+55.7%)
|
-58.42M
est: -110.01M (+46.9%)
|
-102.25M
est: -61.30M (-66.8%)
|
-70.80M
est: -86.82M (+18.5%)
|
-130.87M
est: -152.42M (+14.1%)
|
-231.96M
est: -219.63M (-5.6%)
|
-261.41M
-302.72M – -220.09M
-19.0% YoY
|
-269.47M
-365.76M – -105.43M
-3.1% YoY
|
-147.00M
-194.44M – 23.97M
+45.4% YoY
|
49.50M
-12.06M – 156.56M
+133.7% YoY
|
193.50M
-47.16M – 612.06M
+290.9% YoY
|
| SGA |
8.06M
est: 35.21M (-77.1%)
|
9.01M
est: 3.66M (+146.5%)
|
11.24M
est: 9.62M (+16.7%)
|
13.06M
est: 3.89M (+235.7%)
|
47.71M
est: 24.76M (+92.7%)
|
46.02M
est: 59.90M (-23.2%)
|
53.08M
est: 46.23M (+14.8%)
|
60.32M
est: 54.23M (+11.2%)
|
51.79M
est: 69.34M (-25.3%)
|
52.49M
est: 58.55M (-10.3%)
|
51.70M
est: 43.71M (+18.3%)
|
2.13M
1.62M – 2.63M
-95.1% YoY
|
65.60M
1.54M – 158.85M
+2,983.5% YoY
|
391.94M
16.96M – 1.04B
+497.5% YoY
|
776.58M
33.61M – 2.07B
+98.1% YoY
|
1.16B
50.36M – 3.10B
+49.8% YoY
|
| EPS |
2.16
est: -0.40 (+640.0%)
|
-6.81
est: -6.15 (-10.7%)
|
-5.23
est: -5.13 (-1.9%)
|
-11.50
est: -11.50 (+0.0%)
|
-6.04
est: -5.68 (-6.4%)
|
-3.54
est: -1.82 (-94.5%)
|
-2.03
est: -1.95 (-3.9%)
|
-2.74
est: -2.19 (-25.4%)
|
-1.82
est: -1.86 (+2.2%)
|
-2.32
est: -2.17 (-6.8%)
|
-3.17
est: -3.03 (-4.5%)
|
-3.55
-4.13 – -3.00
-17.1% YoY
|
-2.88
-4.99 – -1.44
+19.0% YoY
|
-1.27
-2.65 – 0.33
+55.8% YoY
|
0.68
-0.16 – 2.14
+153.1% YoY
|
2.64
-0.64 – 8.36
+290.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-286.12M
OE per share TTM
-3.69
Owner's Yield
-24.81%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
30.1%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
42
Total invested
75.55M
Insider transactions (90d)
1
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Southeastern Asset Management, Inc. | 106.85M | 18.90% | 4.00 | 4.00 | 4.00 | 4.00 | IA | Delaware | 2022-02-03 | ↗ |
| 2 | Franklin Resources, Inc. | 8.33M | 5.50% | 8.09M | — | 8.09M | — | HC | California | 2022-02-03 | ↗ |
| 3 | Bihua Chen | 6.04M | 12.36% | — | 6.04M | — | — | IN | United States | 2023-12-14 | ↗ |
| 4 | Cormorant Asset Management, LP | 6.04M | 12.36% | — | 6.04M | — | — | PN | Delaware | 2023-12-14 | ↗ |
| 5 | Cormorant Global Healthcare GP, LLC | 6.04M | 12.36% | — | 6.04M | — | — | OO | Delaware | 2023-12-14 | ↗ |
| 6 | Cormorant Global Healthcare Master Fund, LP | 6.04M | 12.36% | — | 6.04M | — | — | PN | Cayman Islands | 2023-12-14 | ↗ |
| 7 | Adage Capital Management, L.P. | 5.16M | 10.35% | — | 5.16M | — | — | IA, PN | Delaware | 2024-04-30 | ↗ |
| 8 | Phillip Gross | 5.16M | 10.35% | — | 5.16M | — | — | HC, IN | United States | 2024-04-30 | ↗ |
| 9 | Robert Atchinson | 5.16M | 10.35% | — | 5.16M | — | — | HC, IN | United States | 2024-04-30 | ↗ |
| 10 | (1) BlackRock, Inc. | 4.16M | 7.80% | 4.08M | — | 4.16M | — | HC | Delaware | 2024-11-08 | ↗ |
| 11 | Ann C. Donahue | 3.71M | 5.44% | — | 3.71M | — | 3.71M | IN | United States | 2024-11-06 | ↗ |
| 12 | Federated Hermes, Inc. | 3.71M | 5.44% | 3.71M | — | 3.71M | — | HC | Pennsylvania | 2024-11-06 | ↗ |
| 13 | J. Christopher Donahue | 3.71M | 5.44% | — | 3.71M | — | 3.71M | IN | United States | 2024-11-06 | ↗ |
| 14 | Thomas R. Donahue | 3.71M | 5.44% | — | 3.71M | — | 3.71M | IN | United States | 2024-11-06 | ↗ |
| 15 | Voting Shares Irrevocable Trust | 3.71M | 5.44% | 3.71M | — | 3.71M | — | OO | Pennsylvania | 2024-11-06 | ↗ |
| 16 | Chen Yu | 3.57M | 5.20% | — | 3.57M | — | 3.57M | IN | Delaware | 2024-11-07 | ↗ |
| 17 | TCG Crossover Fund II, L.P. | 3.57M | 5.20% | — | 3.57M | — | 3.57M | PN | Delaware | 2024-11-07 | ↗ |
| 18 | TCG Crossover GP II, LLC | 3.57M | 5.20% | — | 3.57M | — | 3.57M | OO | Delaware | 2024-11-07 | ↗ |
| 19 | Aaron Cowen | 3.48M | 9.99% | — | 3.48M | — | 3.48M | HC, IN | — | 2022-02-11 | ↗ |
| 20 | Averill Master Fund, Ltd. | 3.48M | 9.99% | — | 3.48M | — | 3.48M | CO | — | 2022-02-11 | ↗ |
| 21 | Suvretta Capital Management, LLC | 3.48M | 9.99% | — | 3.48M | — | 3.48M | IA, OO | — | 2022-02-11 | ↗ |
| 22 | Ocumension Therapeutics | 3.01M | 16.60% | 3.01M | — | 3.01M | — | CO | — | 2021-01-22 | ↗ |
| 23 | 52-0556948 | 2.52M | 5.60% | 512.6K | — | 2.52M | — | IA | Maryland | 2024-02-14 | ↗ |
| 24 | S | 2.24M | 4.90% | — | 2.24M | — | — | PN | ONTARIO CANADA | 2018-02-09 | ↗ |
| 25 | Adage Capital Advisors, L.L.C. | 1.95M | 5.75% | — | 1.95M | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 26 | Adage Capital Partners GP, L.L.C. | 1.95M | 5.75% | — | 1.95M | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 27 | Adage Capital Partners, L.P. | 1.95M | 5.75% | — | 1.95M | — | — | PN | Delaware | 2022-02-10 | ↗ |
| 28 | Allan Gray Australia Pty Limited (formerly known as Orbis Investment Management (Australia) Pty Limi | 1.77M | 3.90% | 1.77M | — | 1.77M | — | FI | Allan Gray Australia Pty organised under laws Australia | 2018-02-14 | ↗ |
| 29 | Peter Kolchinsky | 1.61M | 5.60% | — | 1.61M | — | 1.61M | HC, IN | United States of America | 2021-08-13 | ↗ |
| 30 | RA Capital Healthcare Fund, L.P. | 1.61M | 5.60% | — | 1.61M | — | 1.61M | PN | Delaware | 2021-08-13 | ↗ |
| 31 | RA Capital Management, L.P. | 1.61M | 5.60% | — | 1.61M | — | 1.61M | IA, PN | Delaware | 2021-08-13 | ↗ |
| 32 | Rajeev Shah | 1.61M | 5.60% | — | 1.61M | — | 1.61M | HC, IN | United States of America | 2021-08-13 | ↗ |
| 33 | 2 | — | 0.00% | — | — | — | — | IA | Delaware | 2018-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
42
-131 vs prev Q
New positions
9
Closed positions
133
Increased
24
Reduced
9
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 981.5K +981.5K (+100.0%) | 17.93B +17.9B (+100.0%) | 1.40% +1.399 pp | 5.93% +5.925 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 2 | CORMORANT ASSET MANAGEMENT, LP | 8.27M -60.0K (-0.7%) | 151.00M +32.5M (+27.4%) | 11.78% -0.127 pp | 6.98% -1.197 pp | USD14.58 +25.3% | 12 qtrs — |
| 3 | SUVRETTA CAPITAL MANAGEMENT, LLC | 7.83M +1.6M (+26.4%) | 143.01M +54.8M (+62.2%) | 11.16% +2.300 pp | 2.93% +0.672 pp | USD11.85 +54.2% | 20 qtrs — |
| 4 | BLACKROCK, INC. | 6.79M +1.8M (+36.7%) | 124.01M +53.3M (+75.4%) | 9.67% +2.574 pp | 0.00% +0.001 pp | USD10.53 +73.5% | 6 qtrs — |
| 5 | FEDERATED HERMES, INC. | 6.02M +1.6M (+36.3%) | 109.94M +47.0M (+74.8%) | 8.58% +2.260 pp | 0.18% +0.073 pp | USD11.00 +66.1% | 13 qtrs — |
| 6 | FRANKLIN RESOURCES INC | 4.98M +805.0K (+19.3%) | 90.93M +31.5M (+53.1%) | 7.09% +1.127 pp | 0.02% +0.008 pp | USD11.80 +54.8% | 21 qtrs — |
| 7 | VANGUARD GROUP INC | 4.82M +1.0M (+27.1%) | 88.10M +34.1M (+63.0%) | 6.87% +1.446 pp | 0.00% +0.001 pp | USD13.18 +38.6% | 21 qtrs — |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.70M -859.8K (-15.5%) | 85.87M +6.7M (+8.5%) | 6.70% -1.253 pp | 0.13% +0.005 pp | USD13.22 +38.2% | 20 qtrs — |
| 9 | PARADIGM BIOCAPITAL ADVISORS LP | 3.69M +1.7M (+84.1%) | 67.44M +38.9M (+136.2%) | 5.26% +2.393 pp | 1.72% +0.909 pp | USD16.08 +13.6% | 2 qtrs — |
| 10 | TCG CROSSOVER MANAGEMENT, LLC | 3.57M +— (+0.0%) | 65.27M +14.4M (+28.3%) | 5.09% -0.018 pp | 2.16% -0.342 pp | USD7.67 +138.2% | 7 qtrs — |
| 11 | JANUS HENDERSON GROUP PLC | 2.94M +2.9M (+100.0%) | 53.66M +53.7M (+100.0%) | 4.19% +4.187 pp | 0.02% +0.024 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 12 | ORBIMED ADVISORS LLC | 2.47M +672.3K (+37.4%) | 45.10M +19.5M (+76.3%) | 3.52% +0.949 pp | 0.92% +0.322 pp | USD15.34 +19.1% | 2 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.90M +374.8K (+24.6%) | 34.71M +13.0M (+59.8%) | 2.71% +0.527 pp | 0.00% +0.001 pp | USD12.20 +49.8% | 21 qtrs — |
| 14 | STATE STREET CORP | 1.83M +361.7K (+24.5%) | 33.52M +12.5M (+59.8%) | 2.61% +0.508 pp | 0.00% +0.000 pp | USD13.29 +37.5% | 19 qtrs — |
| 15 | ABRDN PLC | 1.61M +809.2K (+101.6%) | 29.34M +18.0M (+158.6%) | 2.29% +1.149 pp | 0.05% +0.028 pp | USD13.66 +33.7% | 5 qtrs — |
| 16 | GOLDMAN SACHS GROUP INC | 1.25M -264.8K (-17.5%) | 22.83M +1.3M (+5.9%) | 1.78% -0.385 pp | 0.00% +0.000 pp | USD11.21 +63.0% | 20 qtrs — |
| 17 | PARKMAN HEALTHCARE PARTNERS LLC | 1.09M +1.1M (+100.0%) | 19.88M +19.9M (+100.0%) | 1.55% +1.551 pp | 1.89% +1.892 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 18 | ESSEX WOODLANDS MANAGEMENT, INC. | 1.08M +— (+0.0%) | 19.82M +4.4M (+28.3%) | 1.55% -0.005 pp | 6.23% +1.197 pp | USD6.58 +177.7% | 21 qtrs — |
| 19 | 5AM VENTURE MANAGEMENT, LLC | 1.05M +— (+0.0%) | 19.18M +4.2M (+28.3%) | 1.50% -0.005 pp | 6.03% +0.555 pp | USD8.01 +128.1% | 7 qtrs — |
| 20 | ALYESKA INVESTMENT GROUP, L.P. | 784.4K +583.1K (+289.6%) | 14.33M +11.5M (+399.8%) | 1.12% +0.830 pp | 0.04% +0.032 pp | USD17.25 +5.9% | 9 qtrs — |
| 21 | PATIENT SQUARE CAPITAL LP | 780.0K -231.8K (-22.9%) | 14.25M -158.0K (-1.1%) | 1.11% -0.335 pp | 3.05% -0.803 pp | USD7.85 +132.7% | 6 qtrs — |
| 22 | ARTIA GLOBAL PARTNERS LP | 767.1K +138.7K (+22.1%) | 14.01M +5.1M (+56.6%) | 1.09% +0.195 pp | 2.23% +0.819 pp | USD13.04 +40.1% | 9 qtrs — |
| 23 | ROSALIND ADVISORS, INC. | 690.0K +40.0K (+6.2%) | 12.61M +3.4M (+36.2%) | 0.98% +0.054 pp | 4.43% +1.267 pp | USD14.47 +26.3% | 2 qtrs — |
| 24 | CANDRIAM S.C.A. | 674.4K +674.4K (+100.0%) | 12.32M +12.3M (+100.0%) | 0.96% +0.961 pp | 0.06% +0.061 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 25 | SCHONFELD STRATEGIC ADVISORS LLC | 661.5K +661.5K (+100.0%) | 12.08M +12.1M (+100.0%) | 0.94% +0.943 pp | 0.05% +0.054 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 648.6K +116.8K (+22.0%) | 11.85M +4.3M (+56.5%) | 0.92% +0.164 pp | 0.00% +0.001 pp | USD13.83 +32.1% | 19 qtrs — |
| 27 | BALYASNY ASSET MANAGEMENT L.P. | 595.4K -160.7K (-21.3%) | 10.88M +111.1K (+1.0%) | 0.85% -0.233 pp | 0.01% +0.000 pp | USD14.24 +28.3% | 7 qtrs — |
| 28 | NORTHERN TRUST CORP | 577.6K +73.5K (+14.6%) | 10.55M +3.4M (+47.0%) | 0.82% +0.102 pp | 0.00% +0.000 pp | USD11.67 +56.6% | 21 qtrs — |
| 29 | MILLENNIUM MANAGEMENT LLC | 556.5K +73.4K (+15.2%) | 10.17M +3.3M (+47.8%) | 0.79% +0.102 pp | 0.00% +0.001 pp | USD14.33 +27.5% | 21 qtrs — |
| 30 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 544.1K +544.1K (+100.0%) | 9.94M +9.9M (+100.0%) | 0.78% +0.775 pp | 0.08% +0.078 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 31 | PRINCIPIA WEALTH ADVISORY, LLC | 530.7K +— (+0.0%) | 9.70M +2.1M (+28.3%) | 0.76% -0.003 pp | 6.06% +0.853 pp | USD6.45 +183.3% | 5 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 416.1K -594.2K (-58.8%) | 7.60M -6.8M (-47.2%) | 0.59% -0.852 pp | 0.00% 0.000 pp | USD11.20 +63.1% | 20 qtrs — |
| 33 | DIMENSIONAL FUND ADVISORS LP | 402.1K +173.0K (+75.5%) | 7.34M +4.1M (+125.2%) | 0.57% +0.245 pp | 0.00% +0.001 pp | USD15.26 +19.7% | 19 qtrs — |
| 34 | BLUE OWL CAPITAL HOLDINGS LP | 392.6K +25.0K (+6.8%) | 7.17M +1.9M (+37.0%) | 0.56% +0.034 pp | 0.54% -1.088 pp | USD7.83 +133.3% | 5 qtrs — |
| 35 | SIMPLIFY ASSET MANAGEMENT INC. | 375.3K +284.8K (+314.9%) | 6.86M +5.6M (+432.4%) | 0.53% +0.406 pp | 0.11% +0.088 pp | USD15.43 +18.4% | 4 qtrs — |
| 36 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 366.7K +18.8K (+5.4%) | 6.70M +1.7M (+35.2%) | 0.52% +0.025 pp | 0.29% +0.084 pp | USD9.95 +83.6% | 3 qtrs — |
| 37 | STEMPOINT CAPITAL LP | 353.8K +353.8K (+100.0%) | 6.46M +6.5M (+100.0%) | 0.50% +0.504 pp | 1.11% +1.109 pp | USD18.27 +0.0% | 5 qtrs — |
| 38 | INVESCO LTD. | 339.0K +48.2K (+16.6%) | 6.19M +2.1M (+49.6%) | 0.48% +0.067 pp | 0.00% +0.000 pp | USD13.19 +38.5% | 9 qtrs — |
| 39 | BLEICHROEDER LP | 316.5K +60.0K (+23.4%) | 5.78M +2.1M (+58.3%) | 0.45% +0.084 pp | 1.02% +0.306 pp | USD11.09 +64.7% | 3 qtrs — |
| 40 | MYDA ADVISORS LLC | 300.0K +— (+0.0%) | 5.48M +1.2M (+28.3%) | 0.43% -0.002 pp | 1.04% +0.121 pp | USD13.18 +38.6% | 8 qtrs — |
| 41 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 258.7K +227.1K (+717.4%) | 4.73M +4.3M (+948.7%) | 0.37% +0.324 pp | 0.24% +0.216 pp | USD17.78 +2.8% | 2 qtrs — |
| 42 | BANK OF NEW YORK MELLON CORP | 256.7K +44.8K (+21.2%) | 4.69M +1.7M (+55.5%) | 0.37% +0.063 pp | 0.00% +0.000 pp | USD11.86 +54.0% | 19 qtrs — |
| 43 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 246.3K +246.3K (+100.0%) | 4.50M +4.5M (+100.0%) | 0.35% +0.351 pp | 0.01% +0.005 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 44 | DEUTSCHE BANK AG\ | 226.8K -129.0K (-36.3%) | 4.14M -923.6K (-18.2%) | 0.32% -0.186 pp | 0.00% 0.000 pp | USD13.58 +34.5% | 19 qtrs — |
| 45 | MORGAN STANLEY | 223.7K -754.4K (-77.1%) | 4.09M -9.8M (-70.7%) | 0.32% -1.080 pp | 0.00% -0.001 pp | USD14.50 +26.0% | 21 qtrs — |
| 46 | AMERIPRISE FINANCIAL INC | 213.3K +83.2K (+63.9%) | 3.90M +2.0M (+110.3%) | 0.30% +0.118 pp | 0.00% +0.001 pp | USD13.77 +32.7% | 10 qtrs — |
| 47 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 200.0K +200.0K (+100.0%) | 3.65M +3.7M (+100.0%) | 0.29% +0.285 pp | 0.18% +0.181 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 48 | JANE STREET GROUP, LLC | 197.6K -13.3K (-6.3%) | 3.61M +606.9K (+20.2%) | 0.28% -0.020 pp | 0.00% +0.000 pp | USD12.24 +49.3% | 5 qtrs — |
| 49 | CENTIVA CAPITAL, LP | 196.7K +196.7K (+100.0%) | 3.59M +3.6M (+100.0%) | 0.28% +0.280 pp | 0.03% +0.029 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 50 | UBS GROUP AG | 188.7K -161.5K (-46.1%) | 3.45M -1.5M (-30.9%) | 0.27% -0.232 pp | 0.00% 0.000 pp | USD12.09 +51.1% | 21 qtrs — |
| 51 | WELLINGTON MANAGEMENT GROUP LLP | 188.2K -27.3K (-12.6%) | 3.44M +370.4K (+12.1%) | 0.27% -0.040 pp | 0.00% +0.000 pp | USD7.74 +136.0% | 7 qtrs — |
| 52 | NUVEEN, LLC | 181.3K +76.6K (+73.1%) | 3.31M +1.8M (+122.1%) | 0.26% +0.109 pp | 0.00% +0.001 pp | USD10.85 +68.4% | 4 qtrs — |
| 53 | SCHRODER INVESTMENT MANAGEMENT GROUP | 168.4K -79.4K (-32.0%) | 3.01M -468.6K (-13.5%) | 0.24% -0.114 pp | 0.00% 0.000 pp | USD13.26 +37.8% | 9 qtrs — |
| 54 | BARCLAYS PLC | 140.7K -104.3K (-42.6%) | 2.57M +613.2K (+31.3%) | 0.20% -0.150 pp | 0.00% +0.000 pp | USD12.05 +51.6% | 16 qtrs — |
| 55 | TWO SIGMA INVESTMENTS, LP | 138.5K -41.0K (-22.8%) | 2.53M -25.5K (-1.0%) | 0.20% -0.059 pp | 0.00% 0.000 pp | USD9.63 +89.7% | 17 qtrs — |
| 56 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 137.6K +46.9K (+51.7%) | 2.51M +1.2M (+94.7%) | 0.20% +0.066 pp | 0.00% +0.000 pp | USD11.80 +54.8% | 14 qtrs — |
| 57 | PANAGORA ASSET MANAGEMENT INC | 132.2K +17.9K (+15.7%) | 2.42M +788.2K (+48.4%) | 0.19% +0.025 pp | 0.01% +0.002 pp | USD9.32 +96.0% | 13 qtrs — |
| 58 | CI PRIVATE WEALTH, LLC | 127.5K +— (+0.0%) | 2.33M +513.8K (+28.3%) | 0.18% -0.001 pp | 0.00% +0.000 pp | USD9.41 +94.2% | 8 qtrs — |
| 59 | ESSEX INVESTMENT MANAGEMENT CO LLC | 125.0K -2.8K (-2.2%) | 2.28M +463.2K (+25.5%) | 0.18% -0.005 pp | 0.35% +0.070 pp | USD8.64 +111.5% | 18 qtrs — |
| 60 | BURKEHILL GLOBAL MANAGEMENT, LP | 115.0K +115.0K (+100.0%) | 2.10M +2.1M (+100.0%) | 0.16% +0.164 pp | 0.14% +0.138 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 61 | WOODLINE PARTNERS LP | 100.5K +200.0 (+0.2%) | 1.84M +407.7K (+28.6%) | 0.14% 0.000 pp | 0.01% +0.000 pp | USD7.90 +131.3% | 9 qtrs — |
| 62 | PRICE T ROWE ASSOCIATES INC /MD/ | 92.6K +10.7K (+13.0%) | 1.69M +525.0K (+45.0%) | 0.13% +0.015 pp | 0.00% +0.000 pp | USD15.18 +20.4% | 10 qtrs — |
| 63 | RHUMBLINE ADVISERS | 89.0K -1.3K (-1.5%) | 1.63M +339.7K (+26.4%) | 0.13% -0.002 pp | 0.00% +0.000 pp | USD10.71 +70.6% | 19 qtrs — |
| 64 | WELLS FARGO & COMPANY/MN | 88.3K -45.5K (-34.0%) | 1.61M -291.6K (-15.3%) | 0.13% -0.065 pp | 0.00% 0.000 pp | USD6.75 +170.7% | 21 qtrs — |
| 65 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 87.2K -45.5K (-34.3%) | 1.59M -296.6K (-15.7%) | 0.12% -0.066 pp | 0.05% -0.020 pp | USD6.64 +175.2% | 5 qtrs — |
| 66 | WAVERLY ADVISORS, LLC | 78.1K +45.0K (+135.9%) | 1.43M +954.9K (+202.6%) | 0.11% +0.064 pp | 0.01% +0.007 pp | USD12.83 +42.4% | 4 qtrs — |
| 67 | ALLIANCEBERNSTEIN L.P. | 75.1K +16.5K (+28.2%) | 1.37M +537.6K (+64.4%) | 0.11% +0.023 pp | 0.00% +0.000 pp | USD11.52 +58.6% | 11 qtrs — |
| 68 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 74.9K +13.8K (+22.5%) | 1.37M +497.8K (+57.1%) | 0.11% +0.019 pp | 0.02% +0.007 pp | USD11.04 +65.5% | 3 qtrs — |
| 69 | WOODSTOCK CORP | 68.5K +— (+0.0%) | 1.25M +275.9K (+28.3%) | 0.10% 0.000 pp | 0.11% +0.023 pp | USD14.27 +28.0% | 9 qtrs — |
| 70 | RENAISSANCE TECHNOLOGIES LLC | 61.6K +61.6K (+100.0%) | 1.13M +1.1M (+100.0%) | 0.09% +0.088 pp | 0.00% +0.002 pp | USD18.27 +0.0% | 8 qtrs — |
| 71 | STATE OF WISCONSIN INVESTMENT BOARD | 60.3K -17.2K (-22.2%) | 1.10M -2.3K (-0.2%) | 0.09% -0.025 pp | 0.00% 0.000 pp | USD9.98 +83.1% | 11 qtrs — |
| 72 | ERSTE ASSET MANAGEMENT GMBH | 50.0K +— (+0.0%) | 910.0K +207.5K (+29.5%) | 0.07% 0.000 pp | 0.01% +0.001 pp | USD7.45 +145.2% | 5 qtrs — |
| 73 | VOYA INVESTMENT MANAGEMENT LLC | 47.9K -71.2K (-59.8%) | 875.9K -821.0K (-48.4%) | 0.07% -0.102 pp | 0.00% -0.001 pp | USD9.37 +95.0% | 15 qtrs — |
| 74 | MAREX GROUP PLC | 47.8K +47.8K (+100.0%) | 872.9K +872.9K (+100.0%) | 0.07% +0.068 pp | 0.01% +0.006 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 75 | CITIGROUP INC | 45.5K +30.7K (+207.3%) | 830.9K +620.2K (+294.3%) | 0.06% +0.044 pp | 0.00% +0.000 pp | USD16.09 +13.5% | 20 qtrs — |
| 76 | DEKABANK DEUTSCHE GIROZENTRALE | 35.0K +— (+0.0%) | 792.0K +318.0K (+67.1%) | 0.05% 0.000 pp | 0.00% +0.001 pp | USD23.11 -20.9% | 9 qtrs — |
| 77 | BNP PARIBAS ARBITRAGE, SNC | 43.1K -128.6K (-74.9%) | 787.2K -1.7M (-67.8%) | 0.06% -0.184 pp | 0.00% -0.001 pp | USD8.38 +118.0% | 5 qtrs — |
| 78 | NISA INVESTMENT ADVISORS, LLC | 42.7K +10.2K (+31.2%) | 779.3K +316.5K (+68.4%) | 0.06% +0.014 pp | 0.00% +0.001 pp | USD14.87 +22.9% | 11 qtrs — |
| 79 | METLIFE INVESTMENT MANAGEMENT, LLC | 41.8K +2.1K (+5.2%) | 763.7K +198.1K (+35.0%) | 0.06% +0.003 pp | 0.00% +0.001 pp | USD10.17 +79.6% | 11 qtrs — |
| 80 | LEGATO CAPITAL MANAGEMENT LLC | 40.4K +3.4K (+9.3%) | 738.7K +211.7K (+40.2%) | 0.06% +0.005 pp | 0.06% +0.006 pp | USD8.38 +118.0% | 13 qtrs — |
| 81 | CITADEL ADVISORS LLC | 37.3K -10.6K (-22.1%) | 681.5K -625.0 (-0.1%) | 0.05% -0.015 pp | 0.00% +0.000 pp | USD10.60 +72.4% | 13 qtrs — |
| 82 | JPMORGAN CHASE & CO | 37.2K +6.9K (+22.9%) | 679.4K +248.5K (+57.7%) | 0.05% +0.010 pp | 0.00% +0.000 pp | USD9.96 +83.4% | 20 qtrs — |
| 83 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 35.1K +8.1K (+30.0%) | 641.4K +256.9K (+66.8%) | 0.05% +0.011 pp | 0.00% +0.000 pp | USD10.30 +77.4% | 7 qtrs — |
| 84 | SIMPLEX TRADING, LLC | 34.5K +17.8K (+106.2%) | 630.8K +392.8K (+165.0%) | 0.05% +0.025 pp | 0.00% +0.000 pp | USD16.00 +14.2% | 5 qtrs — |
| 85 | HIGHTOWER ADVISORS, LLC | 32.6K -5.0 (0.0%) | 594.9K +131.2K (+28.3%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD6.97 +162.1% | 21 qtrs — |
| 86 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 32.3K -28.3K (-46.7%) | 590.7K -272.8K (-31.6%) | 0.05% -0.041 pp | 0.01% +0.003 pp | USD14.24 +28.3% | 2 qtrs — |
| 87 | SCOTIA CAPITAL INC. | 31.6K +— (+0.0%) | 577.1K +127.3K (+28.3%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD6.56 +178.5% | 11 qtrs — |
| 88 | CREATIVE PLANNING | 31.2K +9.2K (+41.5%) | 570.4K +256.2K (+81.6%) | 0.04% +0.013 pp | 0.00% +0.000 pp | USD10.19 +79.3% | 5 qtrs — |
| 89 | LONGAEVA PARTNERS L.P. | 30.0K +30.0K (+100.0%) | 548.1K +548.1K (+100.0%) | 0.04% +0.043 pp | 0.05% +0.046 pp | USD18.27 +0.0% | 1 qtrs NEW |
| 90 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 29.5K +7.4K (+33.5%) | 538.8K +224.3K (+71.3%) | 0.04% +0.010 pp | 0.04% +0.015 pp | USD14.91 +22.5% | 9 qtrs — |
| 91 | SEI INVESTMENTS CO | 28.8K +28.8K (+100.0%) | 526.5K +526.5K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.001 pp | USD18.27 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 91 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.74% | 8.22M | 0.35% |
| 2 | Simplify Health Care ETF PINK | 1.47% | 5.61M | 0.51% |
| 3 | Simplify Propel Opportunities ETF SURI | 0.73% | 568.2K | 2.82% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.70% | 400.3K | 0.65% |
| 5 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.54% | 118.9K | 0.20% |
| 6 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.36% | 84.4K | 1.22% |
| 7 | iShares U.S. Pharmaceuticals ETF IHE | 0.26% | 3.50M | 0.38% |
| 8 | iShares Micro-Cap ETF IWC | 0.26% | 3.81M | 0.60% |
| 9 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.11% | 183.6K | 0.51% |
| 10 | iShares Ageing Population UCITS ETF AGED.L | 0.11% | 934.2K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.19
Neutral
Ratio by volume
2.75
Bullish
Buys
31
Sells
26
Shares acquired
1.80M
Shares disposed
656.1K
Cash buys
1.00
Cash sales
3.00
Net activity
+1,148,088
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Ribeiro Ramiro | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,437 | 8.26 | 20.1K | 80,438 | D | ↗ |
| 2026-03-23 | Duker Jay S. | Director / Officer | J-Other | A | Common Stock | 76,766 | 13.11 | 1.01M | 177,431 | I | ↗ |
| 2026-03-16 | Duker Jay S. | Director / Officer | P-Purchase | A | Common Stock | 1,500 | 13.15 | 19.7K | 100,665 | I | ↗ |
| 2026-03-04 | Ribeiro Ramiro | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,438 | 8.26 | 20.1K | 82,875 | D | ↗ |
| 2026-03-02 | Elston George | Officer | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 87,818 | D | ↗ |
| 2026-02-17 | Ribeiro Ramiro | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,437 | 8.26 | 20.1K | 85,313 | D | ↗ |
| 2026-01-06 | Lurker Nancy | Director | M-Exempt | D | Restricted Stock Units | 75,133 | 0.00 | — | 0 | D | ↗ |
| 2026-01-06 | Elston George | Officer | F-InKind | D | Common Stock | 4,487 | 16.86 | 75.7K | 91,852 | D | ↗ |
| 2026-01-06 | Duker Jay S. | Director / Officer | F-InKind | D | Common Stock | 10,054 | 16.86 | 169.5K | 77,752 | D | ↗ |
| 2026-01-05 | Ribeiro Ramiro | Officer | S-Sale | D | Common Stock | 42,544 | 17.10 | 727.3K | 0 | D | ↗ |
| 2026-01-05 | Lurker Nancy | Director | M-Exempt | D | Restricted Stock Units | 12,666 | 0.00 | — | 12,667 | D | ↗ |
| 2026-01-05 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2026-01-05 | Duker Jay S. | Director / Officer | M-Exempt | D | Restricted Stock Units | 30,000 | 0.00 | — | 30,000 | D | ↗ |
| 2026-01-03 | Ribeiro Ramiro | Officer | F-InKind | D | Common Stock | 6,373 | 17.48 | 111.4K | 13,294 | D | ↗ |
| 2026-01-03 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 19,667 | 0.00 | — | 39,333 | D | ↗ |
| 2026-01-03 | Duker Jay S. | Director / Officer | F-InKind | D | Common Stock | 23,447 | 17.48 | 409.9K | 51,518 | D | ↗ |
| 2026-01-02 | Zaderej Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 17.48 | 699.2K | 40,000 | D | ↗ |
| 2026-01-02 | Sanders Reginald J. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 17.48 | 699.2K | 40,000 | D | ↗ |
| 2026-01-02 | Ribeiro Ramiro | Officer | A-Award | A | Stock Option (Right to Buy) | 171,400 | 17.48 | 3.00M | 171,400 | D | ↗ |
| 2026-01-02 | Lurker Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 17.48 | 699.2K | 40,000 | D | ↗ |
| 2026-01-02 | Landis John B. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 17.48 | 699.2K | 40,000 | D | ↗ |
| 2026-01-02 | Hassan Fred | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 17.48 | 699.2K | 40,000 | D | ↗ |
| 2026-01-02 | Elston George | Officer | A-Award | A | Restricted Stock Units | 63,000 | 0.00 | — | 63,000 | D | ↗ |
| 2026-01-02 | Duty Stuart | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 17.48 | 699.2K | 40,000 | D | ↗ |
| 2026-01-02 | Duker Jay S. | Director / Officer | A-Award | A | Restricted Stock Units | 165,000 | 0.00 | — | 165,000 | D | ↗ |
| 2026-01-02 | DICICCO WENDY F | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 17.48 | 699.2K | 40,000 | D | ↗ |
| 2026-01-02 | ANDO GORAN | Director | A-Award | A | Stock Option (Right to Buy) | 41,500 | 17.48 | 725.4K | 41,500 | D | ↗ |
| 2025-12-19 | Elston George | Officer | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 57,114 | D | ↗ |
| 2025-12-04 | Lurker Nancy | Director | S-Sale | D | Common Stock | 9,300 | 15.11 | 140.5K | 206,547 | D | ↗ |
| 2025-12-04 | Cormorant Asset Management, LP | 10% Owner | S-Sale | D | Common Stock | 60,000 | 15.70 | 942.2K | 8,265,000 | I | ↗ |
| 2025-11-28 | Lurker Nancy | Director | S-Sale | D | Common Stock | 500 | 14.95 | 7.5K | 215,847 | D | ↗ |
| 2025-11-26 | Lurker Nancy | Director | S-Sale | D | Common Stock | 200 | 14.95 | 3.0K | 216,347 | D | ↗ |
| 2025-11-11 | Ribeiro Ramiro | Officer | S-Sale | D | Common Stock | 2,722 | 11.61 | 31.6K | 0 | D | ↗ |
| 2025-09-19 | Elston George | Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 62,114 | D | ↗ |
| 2025-07-11 | Zaderej Karen L. | Director | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 0 | D | ↗ |
| 2025-07-10 | Lurker Nancy | Director | M-Exempt | D | Restricted Stock Units | 11,111 | 0.00 | — | 11,112 | D | ↗ |
| 2025-07-10 | Duker Jay S. | Director / Officer | M-Exempt | A | Common Stock | 16,667 | 0.00 | — | 17,653 | D | ↗ |
| 2025-07-02 | Lurker Nancy | Director | G-Gift | D | Stock Option (Right to Buy) | 55,000 | 10.13 | 557.2K | 40,000 | D | ↗ |
| 2025-06-23 | Duker Jay S. | Director / Officer | J-Other | D | Common Stock | 56,665 | 8.21 | 465.2K | 986 | D | ↗ |
| 2025-05-25 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 7,500 | 0.00 | — | 7,500 | D | ↗ |
| 2025-05-19 | Zaderej Karen L. | Director | P-Purchase | A | Common Stock | 5,000 | 5.99 | 30.0K | 36,500 | D | ↗ |
| 2025-05-16 | Zaderej Karen L. | Director | P-Purchase | A | Common Stock | 5,000 | 5.81 | 29.1K | 31,500 | D | ↗ |
| 2025-05-15 | Zaderej Karen L. | Director | P-Purchase | A | Common Stock | 5,000 | 5.47 | 27.4K | 26,500 | D | ↗ |
| 2025-05-14 | Zaderej Karen L. | Director | P-Purchase | A | Common Stock | 5,000 | 5.42 | 27.1K | 21,500 | D | ↗ |
| 2025-03-19 | Duker Jay S. | Director / Officer | J-Other | D | Common Stock | 20,000 | 6.16 | 123.1K | 57,651 | D | ↗ |
| 2025-02-09 | Lurker Nancy | Director | M-Exempt | A | Common Stock | 20,000 | 0.00 | — | 205,436 | D | ↗ |
| 2025-02-09 | Elston George | Officer | M-Exempt | A | Common Stock | 5,834 | 0.00 | — | 75,550 | D | ↗ |
| 2025-02-09 | Duker Jay S. | Director / Officer | M-Exempt | A | Common Stock | 7,000 | 0.00 | — | 79,706 | D | ↗ |
| 2025-01-08 | Sanders Reginald J. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-06 | Lurker Nancy | Director | M-Exempt | A | Common Stock | 75,134 | 0.00 | — | 185,436 | D | ↗ |
| 2025-01-06 | Elston George | Officer | M-Exempt | A | Common Stock | 15,285 | 0.00 | — | 73,374 | D | ↗ |
| 2025-01-06 | Duker Jay S. | Director / Officer | F-InKind | D | Common Stock | 6,108 | 8.68 | 53.0K | 72,706 | D | ↗ |
| 2025-01-05 | Lurker Nancy | Director | M-Exempt | A | Common Stock | 12,667 | 0.00 | — | 110,302 | D | ↗ |
| 2025-01-05 | Landis John B. | Director | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 21,400 | D | ↗ |
| 2025-01-05 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 30,000 | D | ↗ |
| 2025-01-05 | Duker Jay S. | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 0.00 | — | 68,027 | D | ↗ |
| 2025-01-03 | Zaderej Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 8.26 | 330.4K | 40,000 | D | ↗ |
| 2025-01-03 | Ribeiro Ramiro | Officer | A-Award | A | Restricted Stock Units | 59,000 | 0.00 | — | 59,000 | D | ↗ |
| 2025-01-03 | Lurker Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 8.26 | 330.4K | 40,000 | D | ↗ |
| 2025-01-03 | Landis John B. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 8.26 | 330.4K | 40,000 | D | ↗ |
| 2025-01-03 | Hassan Fred | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 8.26 | 330.4K | 40,000 | D | ↗ |
| 2025-01-03 | Elston George | Officer | A-Award | A | Stock Option (Right to Buy) | 117,000 | 8.26 | 966.4K | 117,000 | D | ↗ |
| 2025-01-03 | Duty Stuart | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 8.26 | 330.4K | 40,000 | D | ↗ |
| 2025-01-03 | Duker Jay S. | Director / Officer | A-Award | A | Restricted Stock Units | 195,000 | 0.00 | — | 228,334 | D | ↗ |
| 2025-01-03 | DICICCO WENDY F | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 8.26 | 330.4K | 40,000 | D | ↗ |
| 2025-01-03 | ANDO GORAN | Director | A-Award | A | Stock Option (Right to Buy) | 41,500 | 8.26 | 342.8K | 41,500 | D | ↗ |
| 2024-09-03 | Hassan Fred | Director | A-Award | A | Stock Options (Right to buy) | 60,000 | 8.16 | 489.6K | 60,000 | — | ↗ |
| 2024-08-21 | ANDO GORAN | Director | P-Purchase | A | Common Stock | 5,000 | 7.95 | 39.8K | 13,150 | — | ↗ |
| 2024-08-20 | DICICCO WENDY F | Director | P-Purchase | A | Common Stock | 2,567 | 7.79 | 20.0K | 9,967 | — | ↗ |
| 2024-08-19 | Zaderej Karen L. | Director | P-Purchase | A | Common Stock | 12,500 | 7.98 | 99.8K | 16,500 | — | ↗ |
| 2024-08-16 | Lurker Nancy | Director | P-Purchase | A | Common Stock | 3,173 | 7.88 | 25.0K | 97,635 | — | ↗ |
| 2024-07-26 | Lurker Nancy | Director | G-Gift | D | Stock Option (Right to Buy) | 56,350 | 3.26 | 183.7K | 281,750 | — | ↗ |
| 2024-07-12 | GUYER DAVID R | Director | M-Exempt | D | Stock Option (Right to Buy) | 6,525 | 3.26 | 21.3K | 6,525 | — | ↗ |
| 2024-07-11 | Zaderej Karen L. | Director | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 4,000 | — | ↗ |
| 2024-07-10 | Lurker Nancy | Director / Officer | M-Exempt | A | Common Stock | 11,111 | 0.00 | — | 94,462 | — | ↗ |
| 2024-07-10 | Duker Jay S. | Director / Officer | M-Exempt | A | Common Stock | 16,666 | 0.00 | — | 46,086 | — | ↗ |
| 2024-06-23 | ADAMIS ANTHONY P | Director | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 4,000 | — | ↗ |
| 2024-06-03 | GUYER DAVID R | Director | M-Exempt | A | Common Stock | 6,525 | 3.26 | 21.3K | 12,075 | — | ↗ |
| 2024-05-25 | Elston George | Officer | M-Exempt | A | Common Stock | 7,500 | 0.00 | — | 51,107 | — | ↗ |
| 2024-05-14 | GUYER DAVID R | Director | M-Exempt | A | Common Stock | 6,525 | 3.26 | 21.3K | 13,925 | — | ↗ |
| 2024-05-06 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 207,153 | 12.36 | 2.56M | 8,325,000 | — | ↗ |
| 2024-04-18 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 186,521 | 18.90 | 3.53M | 7,475,000 | — | ↗ |
| 2024-04-18 | Adage Capital Management, L.P. | 10% Owner | — | I | Common Stock, par value $0.001 per share ("Common Stock") | 0 | 0.00 | — | 5,156,299 | — | ↗ |
| 2024-03-30 | Paggiarino Dario A. | Officer | F-InKind | D | Common Stock | 2,957 | 20.67 | 61.1K | 74,176 | — | ↗ |
| 2024-03-01 | Ribeiro Ramiro | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 28.00 | 3.50M | 125,000 | — | ↗ |
| 2024-02-20 | Duker Jay S. | Director / Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 31,920 | — | ↗ |
| 2024-02-13 | Lurker Nancy | Director / Officer | G-Gift | A | Common Stock | 74,681 | 0.00 | — | 126,889 | — | ↗ |
| 2024-02-09 | Paggiarino Dario A. | Officer | M-Exempt | A | Common Stock | 5,833 | 0.00 | — | 47,305 | — | ↗ |
| 2024-02-09 | Lurker Nancy | Director / Officer | M-Exempt | D | Restricted Stock Units | 17,534 | 0.00 | — | 0 | — | ↗ |
| 2024-02-09 | Jones David Scott | Officer | F-InKind | D | Common Stock | 1,701 | 28.80 | 49.0K | 44,916 | — | ↗ |
| 2024-02-09 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 4,967 | 0.00 | — | 0 | — | ↗ |
| 2024-02-09 | Duker Jay S. | Director / Officer | F-InKind | D | Common Stock | 2,075 | 28.80 | 59.8K | 53,378 | — | ↗ |
| 2024-02-02 | Jones David Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 209 | 11.47 | 2.4K | 4,375 | — | ↗ |
| 2024-01-26 | Paggiarino Dario A. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 33,665 | 13.13 | 442.0K | 17,588 | — | ↗ |
| 2024-01-26 | Jones David Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,604 | 12.90 | 123.9K | 8,721 | — | ↗ |
| 2024-01-25 | Paggiarino Dario A. | Officer | S-Sale | D | Common Stock | 300 | 25.00 | 7.5K | 36,505 | — | ↗ |
| 2024-01-25 | Jones David Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 300 | 3.26 | 978.00 | 85,155 | — | ↗ |
| 2024-01-24 | Paggiarino Dario A. | Officer | M-Exempt | A | Common Stock | 5,600 | 13.13 | 73.5K | 47,756 | — | ↗ |
| 2024-01-24 | Lurker Nancy | Director / Officer | S-Sale | D | Common Stock | 29,956 | 24.98 | 748.2K | 135,441 | — | ↗ |
| 2024-01-24 | Jones David Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,700 | 3.26 | 18.6K | 85,455 | — | ↗ |
| 2024-01-23 | Paggiarino Dario A. | Officer | M-Exempt | A | Common Stock | 2,039 | 12.90 | 26.3K | 41,640 | — | ↗ |
| 2024-01-23 | Lurker Nancy | Director / Officer | S-Sale | D | Common Stock | 5,044 | 24.97 | 125.9K | 165,397 | — | ↗ |
| 2024-01-23 | Jones David Scott | Officer | M-Exempt | A | Common Stock | 500 | 3.26 | 1.6K | 38,862 | — | ↗ |
| 2024-01-22 | Jones David Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,416 | 11.47 | 62.1K | 4,584 | — | ↗ |
| 2024-01-11 | Ocumension Therapeutics | Director | S-Sale | D | common stock | 1,910,500 | 19.45 | 37.16M | 100,221 | — | ↗ |
| 2024-01-11 | Liu Ye | Director | S-Sale | D | Common Stock, $0.001 par value | 1,910,500 | 19.45 | 37.16M | 100,221 | — | ↗ |
| 2024-01-11 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 750,000 | 19.75 | 14.81M | 6,893,235 | — | ↗ |
| 2024-01-09 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 105,000 | 21.32 | 2.24M | 6,143,235 | — | ↗ |
| 2024-01-08 | Paggiarino Dario A. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 22,913 | 3.26 | 74.7K | 68,742 | — | ↗ |
| 2024-01-06 | Pine Michael Craig | Officer | F-InKind | D | Common Stock | 5,966 | 20.40 | 121.7K | 13,662 | — | ↗ |
| 2024-01-06 | Paggiarino Dario A. | Officer | M-Exempt | D | Restricted Stock Units | 15,285 | 0.00 | — | 30,570 | — | ↗ |
| 2024-01-06 | Lurker Nancy | Director / Officer | M-Exempt | D | Restricted Stock Units | 75,133 | 0.00 | — | 150,267 | — | ↗ |
| 2024-01-06 | Jones David Scott | Officer | M-Exempt | D | Restricted Stock Units | 15,285 | 0.00 | — | 30,570 | — | ↗ |
| 2024-01-06 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 15,285 | 0.00 | — | 30,570 | — | ↗ |
| 2024-01-06 | Duker Jay S. | Director / Officer | F-InKind | D | Common Stock | 6,528 | 20.40 | 133.2K | 43,486 | — | ↗ |
| 2024-01-05 | Zaderej Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 25,014 | 20.40 | 510.3K | 25,014 | — | ↗ |
| 2024-01-05 | Pine Michael Craig | Officer | A-Award | A | Stock Option (Right to Buy) | 42,000 | 20.40 | 856.8K | 42,000 | — | ↗ |
| 2024-01-05 | Paggiarino Dario A. | Officer | A-Award | A | Stock Option (Right to Buy) | 42,000 | 20.40 | 856.8K | 42,000 | — | ↗ |
| 2024-01-05 | Lurker Nancy | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 77,000 | 20.40 | 1.57M | 77,000 | — | ↗ |
| 2024-01-05 | Landis John B. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 20.40 | 408.0K | 20,000 | — | ↗ |
| 2024-01-05 | Jones David Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 42,000 | 20.40 | 856.8K | 42,000 | — | ↗ |
| 2024-01-05 | GUYER DAVID R | Director | A-Award | A | Stock Option (Right to Buy) | 25,014 | 20.40 | 510.3K | 25,014 | — | ↗ |
| 2024-01-05 | Elston George | Officer | A-Award | A | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2024-01-05 | Duty Stuart | Director | A-Award | A | Stock Option (Right to Buy) | 25,014 | 20.40 | 510.3K | 25,014 | — | ↗ |
| 2024-01-05 | Duker Jay S. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 180,000 | 20.40 | 3.67M | 180,000 | — | ↗ |
| 2024-01-05 | DICICCO WENDY F | Director | A-Award | A | Stock Option (Right to Buy) | 25,014 | 20.40 | 510.3K | 25,014 | — | ↗ |
| 2024-01-05 | ANDO GORAN | Director | A-Award | A | Stock Option (Right to Buy) | 23,598 | 20.40 | 481.4K | 23,598 | — | ↗ |
| 2024-01-05 | ADAMIS ANTHONY P | Director | A-Award | A | Stock Option (Right to Buy) | 25,014 | 20.40 | 510.3K | 25,014 | — | ↗ |
| 2023-12-28 | Lurker Nancy | Director / Officer | G-Gift | D | Common Stock | 52,208 | 0.00 | — | 118,351 | D | ↗ |
| 2023-12-13 | Paggiarino Dario A. | Officer | S-Sale | D | Common Stock | 1,458 | 20.00 | 29.2K | 25,707 | — | ↗ |
| 2023-12-08 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 588,235 | 17.00 | 10.00M | 6,038,235 | — | ↗ |
| 2023-12-06 | Ocumension Therapeutics | Director | S-Sale | D | common stock | 266,242 | 18.41 | 4.90M | 2,010,721 | — | ↗ |
| 2023-12-06 | Liu Ye | Director | S-Sale | D | Common Stock, $0.001 par value | 266,242 | 18.41 | 4.90M | 2,010,721 | — | ↗ |
| 2023-12-05 | Ocumension Therapeutics | Director | S-Sale | D | common stock | 733,758 | 19.91 | 14.61M | 2,276,963 | — | ↗ |
| 2023-12-05 | Liu Ye | Director | S-Sale | D | Common Stock, $0.001 par value | 733,758 | 19.91 | 14.61M | 2,276,963 | — | ↗ |
| 2023-12-04 | Pine Michael Craig | Officer | M-Exempt | D | Stock Option (Right to Buy) | 45,000 | 12.62 | 567.9K | 55,000 | — | ↗ |
| 2023-12-04 | Paggiarino Dario A. | Officer | M-Exempt | A | Common Stock | 30,625 | 10.13 | 310.2K | 56,332 | — | ↗ |
| 2023-12-04 | Lurker Nancy | Director / Officer | S-Sale | D | Common Stock | 20,000 | 20.76 | 415.2K | 170,559 | — | ↗ |
| 2023-12-04 | Cormorant Asset Management, LP | 10% Owner | P-Purchase | A | Common Stock | 37,081 | 24.01 | 890.3K | 5,065,467 | — | ↗ |
| 2023-10-16 | Elston George | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 8.23 | 246.9K | 30,000 | — | ↗ |
| 2023-10-16 | Duty Stuart | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 8.23 | 493.8K | 60,000 | — | ↗ |
| 2023-09-01 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 20,000 | 9.90 | 198.0K | 3,490,921 | — | ↗ |
| 2023-08-31 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 71,478 | 10.17 | 726.7K | 3,517,938 | — | ↗ |
| 2023-08-30 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 327 | 11.36 | 3.7K | 3,589,416 | — | ↗ |
| 2023-08-29 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 87,289 | 10.74 | 937.7K | 3,650,957 | — | ↗ |
| 2023-08-28 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 60,858 | 11.71 | 712.7K | 3,738,246 | — | ↗ |
| 2023-08-25 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 72,925 | 11.09 | 808.7K | 3,810,835 | — | ↗ |
| 2023-08-24 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 87,100 | 11.54 | 1.01M | 3,935,940 | — | ↗ |
| 2023-08-23 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 121,103 | 13.05 | 1.58M | 4,023,040 | — | ↗ |
| 2023-08-22 | EW Healthcare Partners, L.P. | 10% Owner | S-Sale | D | Common Stock, $0.001 par value | 46,778 | 14.62 | 683.8K | 4,144,143 | — | ↗ |
| 2023-07-11 | Zaderej Karen L. | Director | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 4,000 | — | ↗ |
| 2023-07-10 | Lurker Nancy | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 66,666 | 9.11 | 607.3K | 66,666 | — | ↗ |
| 2023-07-10 | Duker Jay S. | Director / Officer | A-Award | A | Restricted Stock Units | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-06-23 | ADAMIS ANTHONY P | Director | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 4,000 | — | ↗ |
| 2023-06-20 | Zaderej Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 26,100 | 3.26 | 85.1K | 26,100 | — | ↗ |
| 2023-06-20 | Pine Michael Craig | Officer | A-Award | A | Restricted Stock Units | 45,855 | 0.00 | — | 45,855 | — | ↗ |
| 2023-06-20 | Paggiarino Dario A. | Officer | A-Award | A | Restricted Stock Units | 45,855 | 0.00 | — | 45,855 | — | ↗ |
| 2023-06-20 | Lurker Nancy | Director / Officer | A-Award | A | Restricted Stock Units | 225,400 | 0.00 | — | 225,400 | — | ↗ |
| 2023-06-20 | Landis John B. | Director | A-Award | A | Stock Option (Right to Buy) | 13,000 | 3.50 | 45.5K | 13,000 | — | ↗ |
| 2023-06-20 | Jones David Scott | Officer | A-Award | A | Restricted Stock Units | 45,855 | 0.00 | — | 45,855 | — | ↗ |
| 2023-06-20 | GUYER DAVID R | Director | A-Award | A | Stock Option (Right to Buy) | 26,100 | 3.26 | 85.1K | 26,100 | — | ↗ |
| 2023-06-20 | Elston George | Officer | A-Award | A | Restricted Stock Units | 45,855 | 0.00 | — | 45,855 | — | ↗ |
| 2023-06-20 | Duker Jay S. | Officer | A-Award | A | Restricted Stock Units | 62,380 | 0.00 | — | 62,380 | — | ↗ |
| 2023-06-20 | DICICCO WENDY F | Director | A-Award | A | Stock Option (Right to Buy) | 26,100 | 3.26 | 85.1K | 26,100 | — | ↗ |
| 2023-06-20 | ANDO GORAN | Director | A-Award | A | Stock Option (Right to Buy) | 13,500 | 3.50 | 47.3K | 13,500 | — | ↗ |
| 2023-06-20 | ADAMIS ANTHONY P | Director | A-Award | A | Stock Option (Right to Buy) | 26,100 | 3.26 | 85.1K | 26,100 | — | ↗ |
| 2023-05-30 | Liu Ye | Director | S-Sale | D | Common Stock, $0.001 par value | 1 | 6.00 | 6.00 | 3,010,721 | — | ↗ |
| 2023-05-25 | Pine Michael Craig | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.93 | 89.0K | 15,000 | — | ↗ |
| 2023-05-25 | Elston George | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 5.93 | 266.9K | 45,000 | — | ↗ |
| 2023-05-11 | Lurker Nancy | Director / Officer | G-Gift | D | Stock Option (right to buy) | 36,000 | 20.40 | 734.4K | 0 | — | ↗ |
| 2023-02-09 | Paggiarino Dario A. | Officer | M-Exempt | A | Common Stock | 4,967 | 0.00 | — | 23,618 | — | ↗ |
| 2023-02-09 | Lurker Nancy | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 0.00 | — | 190,559 | — | ↗ |
| 2023-02-09 | Landis John B. | Director | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 11,400 | — | ↗ |
| 2023-02-09 | Jones David Scott | Officer | M-Exempt | D | Restricted Stock Units | 4,967 | 0.00 | — | 4,967 | — | ↗ |
| 2023-02-09 | GUYER DAVID R | Director | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 7,400 | — | ↗ |
| 2023-02-09 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 5,833 | 0.00 | — | 11,667 | — | ↗ |
| 2023-02-09 | Duker Jay S. | Officer | M-Exempt | D | Restricted Stock Units | 7,000 | 0.00 | — | 14,000 | — | ↗ |
| 2023-02-09 | DICICCO WENDY F | Director | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 7,400 | — | ↗ |
| 2023-02-09 | ANDO GORAN | Director | M-Exempt | A | Common Stock | 3,250 | 0.00 | — | 8,150 | — | ↗ |
| 2023-01-06 | Pine Michael Craig | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 91,655 | 0.00 | — | 91,655 | — | ↗ |
| 2023-01-06 | Paggiarino Dario A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 91,655 | 0.00 | — | 91,655 | — | ↗ |
| 2023-01-06 | Lurker Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 450,800 | 0.00 | — | 450,800 | — | ↗ |
| 2023-01-06 | Jones David Scott | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 91,655 | 0.00 | — | 91,655 | — | ↗ |
| 2023-01-06 | Elston George | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 91,655 | 0.00 | — | 91,655 | — | ↗ |
| 2023-01-06 | Duker Jay S. | Director | A-Award | A | Stock Option (Right to Buy) | 124,755 | 0.00 | — | 124,755 | — | ↗ |
| 2022-11-01 | Duker Jay S. | Director / Officer | M-Exempt | A | Common Stock | 15,258 | 0.00 | — | 25,881 | — | ↗ |
| 2022-09-07 | Duker Jay S. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 65,300 | 0.00 | — | 65,300 | — | ↗ |
| 2022-07-11 | Zaderej Karen L. | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-06-23 | ADAMIS ANTHONY P | Director | A-Award | A | Restricted Stock Units | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2022-03-14 | Pine Michael Craig | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 12.21 | 12.2K | 1,000 | — | ↗ |
| 2022-02-28 | Paggiarino Dario A. | Officer | M-Exempt | A | Common Stock | 4,105 | 0.00 | — | 19,945 | — | ↗ |
| 2022-02-28 | Lurker Nancy | Director / Officer | M-Exempt | A | Common Stock | 12,466 | 0.00 | — | 150,281 | — | ↗ |
| 2022-02-28 | Jones David Scott | Officer | M-Exempt | A | Common Stock | 4,105 | 0.00 | — | 16,729 | — | ↗ |
| 2022-02-21 | Lurker Nancy | Director / Officer | M-Exempt | A | Common Stock | 13,717 | 0.00 | — | 137,815 | — | ↗ |
| 2022-02-09 | Paggiarino Dario A. | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 10.13 | 709.1K | 70,000 | — | ↗ |
| 2022-02-09 | Lurker Nancy | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 240,000 | 10.13 | 2.43M | 240,000 | — | ↗ |
| 2022-02-09 | Landis John B. | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 10.13 | 111.4K | 11,000 | — | ↗ |
| 2022-02-09 | Jones David Scott | Officer | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-02-09 | GUYER DAVID R | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 10.13 | 111.4K | 22,000 | — | ↗ |
| 2022-02-09 | Elston George | Officer | M-Exempt | D | Restricted Stock Units | 4,966 | 0.00 | — | 9,934 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-14.8K
Shares Outstanding
83.80M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jay Duker President and Chief Executive Officer | 696.3K | — | 1.61M | 2.60M | 632.7K | 24.6K | 5.57M | 75.69% | ↗ |
| 2 | 2025 | George Elston Executive Vice President and Chief Financial Officer | 527.7K | — | 487.3K | 781.2K | 352.1K | 25.0K | 2.17M | 58.37% | ↗ |
| 3 | 2025 | Ramiro Ribeiro Chief Medical Officer | 505.0K | — | 487.3K | 781.2K | 359.8K | 23.8K | 2.16M | 58.81% | ↗ |
| 4 | 2024 | Jay Duker President and Chief Executive Officer | 669.5K | — | 1.84M | 2.92M | 498.9K | 25.4K | 5.95M | 79.95% | ↗ |
| 5 | 2024 | Ramiro Ribeiro Chief Medical Officer | 404.2K | 60.0K | — | 2.79M | 276.4K | 2.1K | 3.53M | 78.99% | ↗ |
| 6 | 2024 | George Elston Executive Vice President and Chief Financial Officer | 507.4K | — | 918.0K | 1.46M | 291.9K | 25.2K | 3.20M | 74.28% | ↗ |
| 7 | 2023 | Nancy Lurker Former President and Chief Executive Officer; Current Executive Vice Chair of the Board of Directors | 570.0K | 49.2K | 1.04M | 1.48M | 574.5K | 25.5K | 3.74M | 67.38% | ↗ |
| 8 | 2023 | Jay Duker President and Chief Executive Officer | 614.1K | 47.2K | 658.9K | 961.8K | 605.9K | 27.3K | 2.92M | 55.59% | ↗ |
| 9 | 2023 | George Elston Executive Vice President and Chief Financial Officer | 487.8K | 24.9K | 282.9K | 591.9K | 367.1K | 25.4K | 1.78M | 49.14% | ↗ |
| 10 | 2023 | Dario Paggiarino Former SVP, Chief Medical Officer | 492.4K | 73.0K | 149.5K | 209.0K | 349.6K | 24.7K | 1.30M | 27.62% | ↗ |
| 11 | 2022 | Nancy Lurker Chief Executive Officer | 643.8K | — | 607.8K | 1.64M | 532.2K | 25.0K | 3.45M | 65.14% | ↗ |
| 12 | 2022 | Nancy Lurker Former President and Chief Executive Officer; Current Executive Vice Chair of the Board of Directors | 643.8K | — | 607.8K | 1.64M | 532.2K | 25.0K | 3.45M | 65.14% | ↗ |
| 13 | 2022 | Jay Duker President and Chief Operating Officer | 515.0K | — | 212.7K | 1.00M | 308.8K | 24.8K | 2.06M | 58.88% | ↗ |
| 14 | 2022 | Jay Duker President and Chief Executive Officer | 515.0K | — | 212.7K | 1.00M | 308.8K | 24.8K | 2.06M | 58.88% | ↗ |
| 15 | 2022 | Michael Pine Chief Corporate Development and Strategy Officer | 410.6K | 108.0K | — | 849.4K | 224.4K | 21.8K | 1.61M | 52.62% | ↗ |
| 16 | 2022 | Dario Paggiarino Former SVP, Chief Medical Officer | 472.3K | — | 177.3K | 477.3K | 255.5K | 24.0K | 1.41M | 46.54% | ↗ |
| 17 | 2022 | George Elston Executive Vice President and Chief Financial Officer | 469.1K | — | 177.3K | 477.3K | 253.1K | 23.9K | 1.40M | 46.73% | ↗ |
| 18 | 2021 | Nancy Lurker Chief Executive Officer | 603.2K | — | 690.6K | 1.82M | 490.7K | 15.9K | 3.62M | 69.37% | ↗ |
| 19 | 2021 | Nancy Lurker President and Chief Executive Officer | 603.2K | — | 690.6K | 1.82M | 490.7K | 15.9K | 3.62M | 69.37% | ↗ |
| 20 | 2021 | Jay Duker Chief Operating Officer | 268.7K | 175.0K | 370.6K | 2.33M | 168.7K | 2.6K | 3.31M | 81.44% | ↗ |
| 21 | 2021 | Jay Duker President and Chief Operating Officer | 268.7K | 175.0K | 370.6K | 2.33M | 168.7K | 2.6K | 3.31M | 81.44% | ↗ |
| 22 | 2021 | Scott Jones Chief Commercial Officer | 405.1K | — | 195.6K | 590.0K | 251.1K | 15.9K | 1.46M | 53.90% | ↗ |
| 23 | 2021 | George Elston Chief Financial Officer | 451.6K | — | 195.6K | 514.4K | 276.4K | 15.9K | 1.45M | 48.84% | ↗ |
| 24 | 2020 | Nancy Lurker President and Chief Executive Officer | 582.0K | — | 482.5K | 563.2K | 454.5K | 15.7K | 2.10M | 49.85% | ↗ |
| 25 | 2020 | Dario Paggiarino SVP and Chief Medical Officer | 436.2K | — | 158.9K | 185.4K | 242.4K | 15.7K | 1.04M | 33.15% | ↗ |
| 26 | 2020 | Scott Jones Chief Commercial Officer | 376.3K | — | 158.9K | 185.4K | 212.1K | 15.7K | 948.3K | 36.30% | ↗ |
| 27 | 2020 | George Elston Chief Financial Officer | 440.0K | — | — | 83.1K | 236.9K | 15.7K | 775.7K | 10.71% | ↗ |
| 28 | 2020 | George Elston Chief Financial Officer and Head of Corporate Development | 440.0K | — | — | 83.1K | 236.9K | 15.7K | 775.7K | 10.71% | ↗ |
| 29 | 2019 | Nancy Lurker President and Chief Executive Officer | 577.0K | — | 650.2K | 693.2K | 144.0K | 15.3K | 2.08M | 64.59% | ↗ |
| 30 | 2019 | Dario Paggiarino SVP and Chief Medical Officer | 420.9K | — | — | 275.8K | 105.2K | 15.3K | 817.2K | 33.75% | ↗ |
| 31 | 2019 | George Elston Chief Financial Officer and Head of Corporate Development | 58.4K | 20.0K | — | 635.6K | — | 2.1K | 716.0K | 88.76% | ↗ |
| 32 | 2018 | David Price Chief Financial Officer | 177.1K | 9.0K | — | 493.9K | 90.3K | 9.2K | 779.5K | 63.36% | ↗ |
| 33 | 2018 | Nancy Lurker President and Chief Executive Officer | 281.1K | 15.5K | — | — | 154.6K | 1.8K | 453.0K | 0.00% | ↗ |
| 34 | 2018 | Dario Paggiarino SVP and Chief Medical Officer | 204.2K | 8.7K | — | — | 86.8K | 5.2K | 304.9K | 0.00% | ↗ |
| 35 | 2017 | Nancy Lurker President and Chief Executive Officer | 421.6K | — | 725.0K | 715.9K | 299.2K | 25.5K | 2.19M | 65.88% | ↗ |
| 36 | 2017 | Dario Paggiarino SVP and Chief Medical Officer | 352.9K | — | 53.1K | 645.4K | 137.4K | 5.5K | 1.19M | 58.48% | ↗ |
| 37 | 2017 | Dario Paggiarino VP, Chief Medical Officer | 352.9K | — | 53.1K | 645.4K | 137.4K | 5.5K | 1.19M | 58.48% | ↗ |
| 38 | 2017 | Deb Jorn EVP, Corporate and Commercial Development | 252.1K | — | 297.7K | 466.4K | 158.8K | 9.1K | 1.18M | 64.52% | ↗ |
| 39 | 2017 | Lori Freedman Former VP, Corporate Affairs, General Counsel and Company Secretary | 176.0K | — | — | 278.6K | — | 597.8K | 1.05M | 26.47% | ↗ |
| 40 | 2017 | Paul Ashton Former President and Chief Executive Officer | 99.5K | — | — | — | — | 580.2K | 679.7K | 0.00% | ↗ |
| 41 | 2017 | Leonard Ross VP, Finance and Chief Accounting Officer Former Executive Officers | 262.9K | — | 35.4K | 251.2K | 84.4K | 13.5K | 647.4K | 44.27% | ↗ |
| 42 | 2016 | Paul Ashton President and Chief Executive Officer | 463.5K | 257.2K | — | 735.0K | — | 13.8K | 1.47M | 50.02% | ↗ |
| 43 | 2016 | Paul Ashton Former President and Chief Executive Officer | 463.5K | — | — | 735.0K | 257.2K | 13.8K | 1.47M | 50.02% | ↗ |
| 44 | 2016 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 350.1K | 129.5K | — | 224.1K | — | 14.0K | 717.7K | 31.22% | ↗ |
| 45 | 2016 | Lori Freedman Former VP, Corporate Affairs, General Counsel and Company Secretary | 350.1K | — | — | 224.1K | 129.5K | 14.0K | 717.7K | 31.22% | ↗ |
| 46 | 2016 | Leonard Ross Vice President, Finance | 255.2K | 77.1K | — | 112.0K | — | 14.0K | 458.3K | 24.45% | ↗ |
| 47 | 2016 | Leonard Ross VP, Finance and Chief Accounting Officer Former Executive Officers | 255.2K | — | — | 112.0K | 77.1K | 14.0K | 458.3K | 24.45% | ↗ |
| 48 | 2015 | Paul Ashton President and Chief Executive Officer | 463.5K | 133.8K | — | 815.5K | — | 12.9K | 1.43M | 57.20% | ↗ |
| 49 | 2015 | Paul Ashton Former President and Chief Executive Officer | 463.5K | — | — | 815.5K | 133.8K | 12.9K | 1.43M | 57.20% | ↗ |
| 50 | 2015 | Paul Ashton President and Chief Executive Officer | 463.5K | 133.8K | — | 815.5K | — | 12.9K | 1.43M | 57.20% | ↗ |
| 51 | 2015 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 339.9K | 76.6K | — | 258.3K | — | 13.1K | 687.9K | 37.55% | ↗ |
| 52 | 2015 | Lori Freedman Former VP, Corporate Affairs, General Counsel and Company Secretary | 339.9K | — | — | 258.3K | 76.6K | 13.1K | 687.9K | 37.55% | ↗ |
| 53 | 2015 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 339.9K | 76.6K | — | 258.3K | — | 13.1K | 687.9K | 37.55% | ↗ |
| 54 | 2015 | Leonard Ross Vice President, Finance | 247.8K | 47.9K | — | 155.0K | — | 13.2K | 463.9K | 33.42% | ↗ |
| 55 | 2015 | Leonard S. Ross Vice President, Finance | 247.8K | 47.9K | — | 155.0K | — | 13.2K | 463.9K | 33.42% | ↗ |
| 56 | 2015 | Leonard Ross VP, Finance and Chief Accounting Officer Former Executive Officers | 247.8K | — | — | 155.0K | 47.9K | 13.2K | 463.9K | 33.42% | ↗ |
| 57 | 2014 | Paul Ashton President and Chief Executive Officer | 450.0K | 258.6K | — | 417.2K | — | 15.1K | 1.14M | 36.57% | ↗ |
| 58 | 2014 | Paul Ashton President and Chief Executive Officer | 450.0K | 258.6K | — | 417.2K | — | 15.0K | 1.14M | 36.57% | ↗ |
| 59 | 2014 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 330.0K | 103.5K | — | 189.5K | — | 14.2K | 637.2K | 29.74% | ↗ |
| 60 | 2014 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 330.0K | 103.5K | — | 189.5K | — | 14.1K | 637.2K | 29.75% | ↗ |
| 61 | 2014 | Leonard S. Ross Vice President, Finance | 240.6K | 75.4K | — | 108.3K | — | 14.3K | 438.6K | 24.69% | ↗ |
| 62 | 2014 | Leonard Ross Vice President, Finance | 240.6K | 75.4K | — | 108.3K | — | 14.2K | 438.5K | 24.70% | ↗ |
| 63 | 2013 | Paul Ashton President and Chief Executive Officer | 412.0K | 316.3K | — | 98.4K | — | 13.2K | 840.0K | 11.72% | ↗ |
| 64 | 2013 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 319.3K | 147.1K | — | 72.6K | — | 13.2K | 552.2K | 13.15% | ↗ |
| 65 | 2013 | Leonard S. Ross Vice President, Finance | 218.7K | 84.0K | — | 39.6K | — | 11.4K | 353.7K | 11.20% | ↗ |
| 66 | 2012 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 310.0K | — | — | 305.5K | — | 13.0K | 628.5K | 48.60% | ↗ |
| 67 | 2012 | Paul Ashton President and Chief Executive Officer | 400.0K | — | — | 125.2K | — | 13.5K | 538.8K | 23.24% | ↗ |
| 68 | 2012 | Leonard S. Ross Vice President, Finance | 212.3K | — | — | 145.3K | — | 12.9K | 370.6K | 39.21% | ↗ |
| 69 | 2011 | Paul Ashton President and Chief Executive Officer | 363.0K | 181.5K | — | 872.2K | — | 13.5K | 1.43M | 60.99% | ↗ |
| 70 | 2011 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 294.7K | 88.4K | — | 233.7K | — | 12.9K | 629.7K | 37.11% | ↗ |
| 71 | 2011 | Leonard S. Ross Vice President, Finance | 202.2K | 50.6K | — | 123.5K | — | 12.5K | 388.8K | 31.76% | ↗ |
| 72 | 2010 | Paul Ashton President and Chief Executive Officer | 330.0K | 140.3K | — | 989.8K | — | 12.7K | 1.47M | 67.21% | ↗ |
| 73 | 2010 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 286.1K | 73.0K | — | — | — | 12.7K | 371.8K | 0.00% | ↗ |
| 74 | 2010 | Leonard S. Ross Vice President, Finance | 189.0K | 40.2K | — | — | — | 11.8K | 241.0K | 0.00% | ↗ |
| 75 | 2009 | Paul Ashton President and Chief Executive Officer | 330.0K | 55.0K | 110.0K | 240.4K | — | 12.7K | 748.1K | 46.84% | ↗ |
| 76 | 2009 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 286.1K | 28.6K | 57.2K | 361.5K | — | 12.3K | 745.7K | 56.15% | ↗ |
| 77 | 2009 | Michael J. Soja Former Vice President Finance, Chief Financial Officer and Treasurer | 198.3K | — | — | 91.9K | — | 435.8K | 726.0K | 12.66% | ↗ |
| 78 | 2009 | Leonard S. Ross Vice President, Finance | 158.0K | 39.4K | — | — | — | 9.1K | 358.8K | 0.00% | ↗ |
| 79 | 2009 | Leonard S. Ross Vice President, Finance | 158.0K | 39.4K | — | 40.6K | — | 9.1K | 247.0K | 16.41% | ↗ |
| 80 | 2008 | Paul Ashton President and Chief Executive Officer | 300.0K | 150.0K | — | 30.5K | — | 10.6K | 491.1K | 6.22% | ↗ |
| 81 | 2008 | Paul Ashton Managing Director | 300.0K | 150.0K | — | 12.5K | — | 10.6K | 473.0K | 2.63% | ↗ |
| 82 | 2008 | Aaron Finlay Former Company Secretary | 164.4K | — | — | 50.5K | — | 203.5K | 418.3K | 12.07% | ↗ |
| 83 | 2008 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 272.5K | 81.7K | — | 49.6K | — | 11.9K | 415.8K | 11.93% | ↗ |
| 84 | 2008 | Lori Freedman Vice President of Corporate Affairs , General Counsel and Secretary | 272.5K | 81.7K | — | 35.6K | — | 11.9K | 401.8K | 8.86% | ↗ |
| 85 | 2008 | Michael J. Soja Former Vice President Finance, Chief Financial Officer and Treasurer | 272.5K | 81.7K | — | 35.6K | — | 11.6K | 401.4K | 8.87% | ↗ |
| 86 | 2008 | Michael J. Soja Vice President of Finance, Chief Financial Officer and Treasurer | 272.5K | 81.7K | — | 35.6K | — | 11.6K | 401.4K | 8.87% | ↗ |
| 87 | 2007 | Lori Freedman Vice President of Corporate Affairs , General Counsel and Secretary | 272.5K | 55.3K | 142.9K | 13.8K | — | 14.3K | 498.8K | 31.43% | ↗ |
| 88 | 2007 | Lori Freedman Vice President for Corporate Affairs, General Counsel and Company Secretary | 272.5K | 55.3K | 142.9K | 13.8K | — | 14.3K | 498.8K | 31.43% | ↗ |
| 89 | 2007 | Michael J. Soja Former Vice President Finance, Chief Financial Officer and Treasurer | 272.5K | 54.2K | 136.6K | 13.8K | — | 11.5K | 488.7K | 30.79% | ↗ |
| 90 | 2007 | Michael J. Soja Vice President of Finance, Chief Financial Officer and Treasurer | 272.5K | 54.2K | 136.6K | 13.8K | — | 11.5K | 488.7K | 30.79% | ↗ |
| 91 | 2007 | Lori Freedman Vice President for Corporate Affairs , General Counsel and Company Secretary | 272.5K | 55.3K | 142.9K | 1.1K | — | 14.3K | 486.1K | 29.63% | ↗ |
| 92 | 2007 | Michael J. Soja Vice President of Finance, Chief Financial Officer and Treasurer | 272.5K | 54.2K | 136.6K | 1.1K | — | 11.5K | 476.0K | 28.93% | ↗ |
| 93 | 2007 | Paul Ashton Managing Director | 300.0K | 25.8K | 62.3K | — | — | 13.8K | 401.9K | 15.50% | ↗ |
| 94 | 2007 | Paul Ashton President and Chief Executive Officer | 300.0K | 25.8K | 62.3K | — | — | 13.8K | 401.9K | 15.50% | ↗ |
| 95 | 2007 | Gavin Rezos Former Managing D irector | 63.3K | — | — | — | — | 260.6K | 323.9K | 0.00% | ↗ |
| 96 | 2007 | Gavin Rezos Former Managing Director | 63.3K | — | — | — | — | 260.6K | 323.9K | 0.00% | ↗ |
| 97 | 2007 | Aaron Finlay Former Company Secretary | 244.3K | — | — | — | — | 29.3K | 273.6K | 0.00% | ↗ |
| 98 | 2007 | Aaron Finlay Company Secretary | 244.3K | — | — | — | — | 29.3K | 273.6K | 0.00% | ↗ |
| 99 | 2007 | Roger Brimblecombe Former Acting Chief Executive Officer and Former Chairman of the Board of Directors | 82.0K | — | — | — | — | — | 82.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jay S. Duker | President, Chief Executive Officer & Director | 1M | — |
| George O. Elston | Executive Vice President & Chief Financial Officer | 904.8K | male |
| Ramiro Ribeiro | Chief Medical Officer | 888.6K | — |
| David Scott Jones | Senior Vice President | 672.1K | male |
| Anna Kluczewska | Chief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd | 183.5K | — |
| Michael J. Maciocio | Chief Manufacturing Officer | — | male |
| Ron I. Honig | Chief Legal Officer & Company Secretary | — | male |
| Isabelle Lefebvre | Chief Regulatory Officer | — | female |
| Jennifer Leonard | Chief People Officer & Senior Vice President of IT | — | female |
| Marcia Sellos-Moura | Chief Scientific Officer | — | — |
| Michael Campbell | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EYPT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
